Andrea M. Gross, MD
- Director, Neurofibromatosis Program, Division of Oncology
- Associate Professor, UC Department of Pediatrics
- andrea.gross@cchmc.org
- Board Certified
About
Biography
I am an associate professor of pediatrics and the director of the Neurofibromatosis Program within the Division of Oncology. My clinical focus includes neurofibromatosis, plexiform neurofibromas, malignant peripheral nerve sheath tumors and pediatric solid tumors. My research interests center on developmental therapeutics, functional outcome assessments and preventing neurofibromatosis tumor-related morbidity and mortality.
I received my medical degree from the University of Connecticut School of Medicine. I completed my pediatric residency at Cincinnati Children’s, where I also served as chief resident, followed by a fellowship in pediatric hematology/oncology at Children’s National Hospital in Washington, D.C.
BS: University of Connecticut, 2006.
MD: University of Connecticut School of Medicine, 2010.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 2013.
Chief Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, 2014.
Fellowship: Pediatric Hematology / Oncology, Children's National Hospital, 2017.
Certification: General Pediatrics, American Board of Pediatrics, 2013; Pediatric Hematology / Oncology, American Board of Pediatrics, 2019.
Interests
Neurofibromatosis; plexiform neurofibromas; malignant peripheral nerve sheath tumors; pediatric solid tumors; clinical research
Services and Specialties
Interests
Developmental therapeutics; functional outcome assessments; prevention of tumor-related morbidity and mortality
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
61430 Dermatologic adverse events in neurofibromatosis patients on MEK inhibitors. Journal of the American Academy of Dermatology. 2025; 93:ab33.
Clinicopathologic Features, Management, and Outcomes Of Pediatric CRTC1::TRIM11 and MED15::ATF1 Tumors With Spitzoid Morphology: A Case Series. Pediatric Blood and Cancer. 2025; 72:e31814.
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas. Journal of Clinical Oncology. 2025; 43:1843-1844.
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial. JAMA Dermatology. 2025; 161:533-537.
Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment. Pediatric Research. 2025; 97:1918-1928.
Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1. Neuro-Oncology. 2025; 27:616-624.
A Pilot Acceptance and Commitment Intervention for Parents of Children With RASopathies. Clinical Practice in Pediatric Psychology. 2025; 13:37-48.
A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib. Cancers. 2025; 17:295.
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm. Neuro-Oncology Advances. 2025; 7:vdaf101.
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nature Medicine. 2025; 31:105-115.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey